Matches in Nanopublications for { ?s ?p "[Challenge experiments showed that co-administration of pVAX-IL-21-IL-15 and pVAX-CDPK1 significantly (P < 0.05) increased survival time (19.2 � 5.1 days) compared with pVAX-CDPK1 (17.3 � 4.3 days) or pVAX-IL-21-IL-15 (12.0 � 2.0 days) alone, and pVAX-IL-21-IL-15 +?pVAX-CDPK1 significantly reduced the number of brain cysts (72.7%) in contrast to pVAX-ROP13 (45.7%) or pVAX-IL-21-IL-15 alone (43.6%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1217318.RAcMG699FK7SQgnqaMg9Hbv1vWV2Klt448de5bO7qCXck130_assertion description "[Challenge experiments showed that co-administration of pVAX-IL-21-IL-15 and pVAX-CDPK1 significantly (P < 0.05) increased survival time (19.2 � 5.1 days) compared with pVAX-CDPK1 (17.3 � 4.3 days) or pVAX-IL-21-IL-15 (12.0 � 2.0 days) alone, and pVAX-IL-21-IL-15 +?pVAX-CDPK1 significantly reduced the number of brain cysts (72.7%) in contrast to pVAX-ROP13 (45.7%) or pVAX-IL-21-IL-15 alone (43.6%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1217318.RAcMG699FK7SQgnqaMg9Hbv1vWV2Klt448de5bO7qCXck130_provenance.
- NP1217320.RACNh3xPd9CBVbzS5a65WZaQmwVmJ0gAKVAH4ywJKwX-s130_assertion description "[Challenge experiments showed that co-administration of pVAX-IL-21-IL-15 and pVAX-CDPK1 significantly (P < 0.05) increased survival time (19.2 � 5.1 days) compared with pVAX-CDPK1 (17.3 � 4.3 days) or pVAX-IL-21-IL-15 (12.0 � 2.0 days) alone, and pVAX-IL-21-IL-15 +?pVAX-CDPK1 significantly reduced the number of brain cysts (72.7%) in contrast to pVAX-ROP13 (45.7%) or pVAX-IL-21-IL-15 alone (43.6%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1217320.RACNh3xPd9CBVbzS5a65WZaQmwVmJ0gAKVAH4ywJKwX-s130_provenance.
- NP934639.RA90CyXYrOx2qonHFmnQWKNgNyWKwUzCKCPrYP-yJb8q4130_assertion description "[Challenge experiments showed that co-administration of pVAX-IL-21-IL-15 and pVAX-CDPK1 significantly (P < 0.05) increased survival time (19.2 � 5.1 days) compared with pVAX-CDPK1 (17.3 � 4.3 days) or pVAX-IL-21-IL-15 (12.0 � 2.0 days) alone, and pVAX-IL-21-IL-15 +?pVAX-CDPK1 significantly reduced the number of brain cysts (72.7%) in contrast to pVAX-ROP13 (45.7%) or pVAX-IL-21-IL-15 alone (43.6%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP934639.RA90CyXYrOx2qonHFmnQWKNgNyWKwUzCKCPrYP-yJb8q4130_provenance.
- NP1217321.RA1JPX5WUQKaOnqQgWBXRjXP9OdZfL7rGZPEEOwBpLmDU130_assertion description "[Challenge experiments showed that co-administration of pVAX-IL-21-IL-15 and pVAX-CDPK1 significantly (P < 0.05) increased survival time (19.2 � 5.1 days) compared with pVAX-CDPK1 (17.3 � 4.3 days) or pVAX-IL-21-IL-15 (12.0 � 2.0 days) alone, and pVAX-IL-21-IL-15 +?pVAX-CDPK1 significantly reduced the number of brain cysts (72.7%) in contrast to pVAX-ROP13 (45.7%) or pVAX-IL-21-IL-15 alone (43.6%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1217321.RA1JPX5WUQKaOnqQgWBXRjXP9OdZfL7rGZPEEOwBpLmDU130_provenance.
- NP898031.RAwVbTHK8oGouE2USN3F77TEtmgeLYIuCaWfccfAxNyM4130_assertion description "[Challenge experiments showed that co-administration of pVAX-IL-21-IL-15 and pVAX-CDPK1 significantly (P < 0.05) increased survival time (19.2 � 5.1 days) compared with pVAX-CDPK1 (17.3 � 4.3 days) or pVAX-IL-21-IL-15 (12.0 � 2.0 days) alone, and pVAX-IL-21-IL-15 +?pVAX-CDPK1 significantly reduced the number of brain cysts (72.7%) in contrast to pVAX-ROP13 (45.7%) or pVAX-IL-21-IL-15 alone (43.6%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP898031.RAwVbTHK8oGouE2USN3F77TEtmgeLYIuCaWfccfAxNyM4130_provenance.
- NP887026.RA9_jPLNppHIl66O-NtyzRBCdJwtqV3QzjsPq4ExfJnEk130_assertion description "[Challenge experiments showed that co-administration of pVAX-IL-21-IL-15 and pVAX-CDPK1 significantly (P < 0.05) increased survival time (19.2 � 5.1 days) compared with pVAX-CDPK1 (17.3 � 4.3 days) or pVAX-IL-21-IL-15 (12.0 � 2.0 days) alone, and pVAX-IL-21-IL-15 +?pVAX-CDPK1 significantly reduced the number of brain cysts (72.7%) in contrast to pVAX-ROP13 (45.7%) or pVAX-IL-21-IL-15 alone (43.6%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP887026.RA9_jPLNppHIl66O-NtyzRBCdJwtqV3QzjsPq4ExfJnEk130_provenance.